Markets

Allergan: FDA Approves BOTOX For Pediatric Patients - Quick Facts

(RTTNews) - Allergan plc (AGN) said the U.S. FDA has approved the company's supplemental Biologics License Application, or sBLA, for BOTOX for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. The company noted that the approval marks 11th BOTOX therapeutic indication.

The FDA approval is based on a phase 3 study evaluating the safety and efficacy of BOTOX in more than 300 pediatric patients aged two to 17 years old being treated for lower limb spasticity.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More